29 May 2023 | Monday | News
Image Source : Public Domain
Merck, a leading science and technology company, today announced that 43 abstracts covering several modalities and mechanisms will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, June 2-6, Chicago, Ill., US. New data for the medicines BAVENCIO® (avelumab), ERBITUX® (cetuximab), and TEPMETKO® (tepotinib) and pipeline assets including the first-in-class investigational IAP (inhibitor of apoptosis protein) inhibitor xevinapant demonstrate the Company’s efforts to pioneer novel medicines intended to improve the lives of people living with cancer.
“The research we will present at ASCO 2023 demonstrates that we are not only maximizing the impact of our standard-of-care treatments but also advancing development programs focused on synergistic approaches targeting key cancer pathways and mechanisms,” said Victoria Zazulina, M.D., Head of Development Unit, Oncology, for the Healthcare business of Merck.
Key presentations include:
Additional company-sponsored activity at ASCO:
In addition to the data being presented at ASCO 2023, Merck will launch a new educational initiative for oncology professionals on the unmet medical need in LA SCCHN, cancer’s resistance to apoptosis, and the role of apoptosis proteins. More information on the initiative can be found at www.TheWallinSCCHN.com.
Select Merck-related abstracts accepted for presentation at ASCO 2023 include (all times in CDT):
Title |
Lead Author |
Abstract |
Session Information |
|
BAVENCIO (avelumab) |
||||
Advanced Urothelial Carcinoma |
||||
Long-term safety of avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC) in the JAVELIN Bladder 100 trial |
Bellmunt J |
4516 |
Genitourinary Cancer: Kidney and Bladder Saturday, June 3, 2023 8:00AM-11:00AM Poster Discussion Time: 3:00PM-4:30PM
|
|
Estimated net benefit of avelumab (AVE) + best supportive care (BSC) vs BSC alone for patients (pts) with advanced urothelial carcinoma (aUC) using a quality-adjusted time without cancer symptoms or toxicity (Q-TWiST) analysis
|
Powles T |
4515 |
Genitourinary Cancer: Kidney and Bladder Saturday, June 3, 2023 8:00AM-11:00AM
Poster Discussion Time: 3:00PM-4:30PM |
|
Real-world response (rwR) rates and clinical outcomes of patients treated with first-line (1L) platinum-based chemotherapy (PBC) for advanced urothelial cancer (aUC)
|
Moon HH |
4567 |
Genitourinary Cancer—Kidney and Bladder Saturday, June 3, 2023 8:00 AM-11:00 AM |
|
Metastatic Merkel Cell Carcinoma |
||||
Avelumab as second-line or later (2L+) treatment in patients (pts) with metastatic Merkel cell carcinoma (mMCC): analysis of real-world outcomes in France using the CARADERM registry and the French national healthcare database
|
Blom A |
9537 |
Melanoma/Skin Cancers Saturday, June 3, 2023 1:15PM-4:15PM |
|
Metastatic Colorectal Cancer |
||||
Modified FOLFOXIRI plus cetuximab and avelumab as initial therapy in RAS wild-type unresectable metastatic colorectal cancer: results of the phase II AVETRIC trial by GONO
|
Conca V |
3575 |
Gastrointestinal Cancer: Colorectal and Anal Monday, June 5, 2023 8:00AM-11:00AM |
|
Xevinapant |
|
|
|
|
Phase 3 study of xevinapant plus radiotherapy (RT) for high-risk, cisplatin-ineligible patients with resected, locally advanced squamous cell carcinoma of the head and neck (LA SCCHN)
|
Ferris RL |
TPS6101 |
Head and Neck Cancer Monday, June 5, 2023 1:15PM-4:15PM |
|
Effect of extended treatment with IAP inhibitor xevinapant post radiotherapy (RT) on efficacy and the tumor microenvironment (TME) in preclinical models
|
Yeung TL |
6027 |
Head and Neck Cancer Monday, June 5, 2023 1:15PM-4:15PM |
|
TEPMETKO (tepotinib) |
|
|
|
|
Long-term outcomes of tepotinib in patients with MET exon 14 skipping NSCLC from the VISION study
|
Paik P |
9060 |
Lung Cancer: Non-Small Cell Metastatic Sunday, June 4, 2023 8:00AM-11:00AM
|
|
Tepotinib + osimertinib for EGFR mutant (EGFRm) NSCLC with MET amplification (METamp) after first-line (1L) osimertinib
|
Tan D |
9021 |
Lung Cancer: Non-Small Cell Metastatic Sunday, June 4, 2023 8:00AM-11:00AM Poster Discussion Time: 4:30PM-6:00PM
|
|
Detection of MET amplification (METamp) in patients with EGFR mutant (m) NSCLC after first-line (1L) osimertinib
|
Yu H |
9074 |
Lung Cancer: Non-Small Cell Metastatic Sunday, June 4, 2023 8:00AM-11:00AM |
|
Patients with EGFR-mutant (m) MET-altered NSCLC receiving tepotinib with an EGFR tyrosine kinase inhibitor (TKI): a case series |
Le X |
9070 |
Lung Cancer: Non-Small Cell Metastatic Sunday, June 4, 2023 8:00 AM-11:00 AM
|
|
ERBITUX (cetuximab) |
|
|
|
|
Phase III FIRE-4 study (AIO KRK-0114): Influence of Baseline Liquid Biopsy results in first-line treatment efficacy of FOLFIRI/cetuximab in patients with tissue RAS-WT mCRC
|
Stintzing S |
3507 |
Oral Abstract Session Gastrointestinal Cancer: Colorectal and Anal Sunday, June 4, 2023 8:00AM-11:00AM |
|
Early tumor shrinkage (ETS) as clinical factor to select maintenance with cetuximab (cet) alone in RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts): a secondary endpoint analysis of the ERMES study
|
Orlandi A |
3603 |
Gastrointestinal Cancer: Colorectal and Anal Monday, June 5, 2023 8:00AM-11:00AM
|
|
Prognostic role of TP53 variants in the phase III study of FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab (Cet) alone in first-line therapy of RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients (ERMES study)
|
Normanno N |
3544 |
Gastrointestinal Cancer: Colorectal and Anal Monday, June 5, 2023 8:00AM-11:00AM |
Advancing the Future of Cancer Care
At Merck, we strive every day to improve the futures of people living with cancer. Our research explores the full potential of promising mechanisms in cancer research, focused on synergistic approaches designed to hit cancer at its core. We are determined to maximize the impact of our standard-of-care treatments and to continue pioneering novel medicines. Our vision is to create a world where more cancer patients will become cancer survivors.
Most Read
Bio Jobs
News